ASTRAVION PHARMACEUTICALS presents RABIVION-DSR, an advanced formulation combining Rabeprazole Sodium (Enteric Coated) and Domperidone (Sustained Release) for comprehensive management of acid reflux and related digestive conditions. Rabeprazole belongs to the proton pump inhibitor (PPI) class and works by reducing gastric acid secretion, while Domperidone enhances gastrointestinal motility and helps alleviate symptoms such as nausea, bloating, and fullness.
This synergistic combination is commonly prescribed for the management of gastroesophageal reflux disease (GERD), acid reflux, gastritis, dyspepsia, and other acid-peptic disorders. The enteric-coated Rabeprazole ensures optimal drug delivery, while the sustained-release Domperidone provides prolonged therapeutic action for enhanced patient comfort.
Product Name: RABIVION-DSR
Generic Name/Composition: Rabeprazole Sodium (EC) & Domperidone (SR)
Dosage Form: Capsule
Category: Gastrointestinal / Anti-Ulcerant / Proton Pump Inhibitor & Prokinetic
Indication: Gastroesophageal Reflux Disease (GERD), Acid Reflux, Gastritis, Dyspepsia, Heartburn, Acid-Peptic Disorders
Route of Administration: Oral
Storage Conditions: Store in a cool, dry place below 25°C. Protect from moisture and direct sunlight.
Manufacturer/Marketer: ASTRAVION PHARMACEUTICALS LLP
RABIVION-DSR is a combination gastrointestinal medication from ASTRAVION PHARMACEUTICALS, formulated with Rabeprazole Sodium (EC) and Domperidone (SR). This dual-action formulation is designed to provide effective relief from acid-related disorders and gastrointestinal discomfort. By addressing both excessive stomach acid production and impaired gastric motility, RABIVION-DSR helps improve digestive comfort and supports overall gastrointestinal health.
Helps reduce excessive stomach acid production.
Provides relief from heartburn, acid reflux, and indigestion.
Improves gastric motility and stomach emptying.
Helps reduce nausea, bloating, and abdominal discomfort.
Supports effective management of GERD and acid-peptic disorders.
Sustained-release formulation offers prolonged symptom control.